Clinical Trials Logo

Filter by:
NCT ID: NCT05989100 Recruiting - Stroke Clinical Trials

Taste Stimulation for Post-stroke Dysphagia

Start date: September 1, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical study is to compare the effect of favourate taste stimulation of oral cavity and tounge, with sour and traditional single thermal stimulation in post-stroke patients with dysphagia. The main questions it aims to answer are: 1. Whether favourate taste stimulation of oral and tounge is better than traditional thermal stimulation in improving swallowing function of patients with dysphagia. 2. It has been reported that taste of sour stimulation can increase the frequency of swallowing. In this study, we want to know which is better for improving swallowing function between favourate taste stimulation and sour taste stimulation. 3. Functional near-infrared spectroscopy (fNIRS) will be applied in this study to understand the neural mechanism of taste stimulation in improving swallowing function. Participants screened as post-stroke dysphagia will accept swallowing evaluation and fNIRS test before and after treatment. The treatment include taste stimulation and traditional swallowing training. Researchers will compare favourate taste stimulation with sour-taste stimulation and single thermal stimulation to see if the swallowing function improved faster and better in favourate taste stimulation group.

NCT ID: NCT05989048 Recruiting - Migraine Clinical Trials

A Study to Learn About Zavegepant as the Acute Treatment of Migraine in Asian Adults

Start date: November 29, 2023
Phase: Phase 3
Study type: Interventional

The purpose of this study is to learn how safe and effective zavegepant is compared to placebo in the acute treatment of migraine in Asian adults. Migraine is a very painful headache with other associated symptoms such as nausea, photophobia and phonophobia. A placebo is a harmless treatment that has no medical effect. This study is seeking for participants who: - have at least 1 year of migraine history before entering the study. - have 2 to 8 migraine headache attacks of moderate or severe intensity in each of the 3 months before entering the study. - have less than 15 days with headaches in each of the 3 months before entering the study. The headaches could be either due to migraine or not. The participants in this study will receive zavegepant or placebo through intranasal route. Intranasal means medicine which is given through nose. Zavegepant or placebo will be taken if the participants have a migraine headache of moderate or severe intensity. The study will compare the experiences of people receiving zavegepant to those of the people receiving placebo. This will help see if zavegepant is safe and effective in Asian adults. Participants will be in this study for up to about 16 weeks. Participants will have 3 study visits at the study clinic and 1 through telephone contact.

NCT ID: NCT05988879 Recruiting - Hepatitis B Clinical Trials

Functional Cure of Hepatitis B in HIV/HBV Co-infected Patients

Start date: August 2, 2023
Phase:
Study type: Observational

Evaluate the potential of ART combined with interferon therapy to achieve functional cure of hepatitis B in HIV/HBV co-infected patients

NCT ID: NCT05988450 Active, not recruiting - Clinical trials for Functional Mitral Regurgitation

Safety and Effectiveness Study of SQ-Kyrin TMVr System for Functional Mitral Regurgitation

Start date: March 7, 2022
Phase: N/A
Study type: Interventional

To verify the safety and effectiveness of transcatheter mitral valve clip delivery system and steerable guide catheter produced by Shanghai Shenqi Medical Technology Co., Ltd. in patients with moderate-severe (3 +) or severe (4 +) functional MR (functional MR) who still have symptoms after full treatment.

NCT ID: NCT05988372 Not yet recruiting - Clinical trials for Locally Advanced Pancreatic Cancer

Surufatinib and Serplulimab Combined With AG Regimen Compare With AG Regimen as Conversion Therapy for Patients With Locally Advanced Pancreatic Cancer (SAGE)

Start date: October 23, 2023
Phase: Phase 2
Study type: Interventional

This is a Phase II Randomized Controlled PILOT clinical study. The purpose of this study is to explore the efficacy and safety of surufatinib and serplulimab in combination with albumin-paclitaxel and gemcitabine in the conversion therapy for patients with unresectable locally advanced pancreatic cancer. Furthermore, it compares the efficacy of surufatinib and serplulimab in combination with albumin-paclitaxel and gemcitabine to the albumin-paclitaxel and gemcitabine regimen in the conversion therapy for patients with unresectable locally advanced pancreatic cancer.

NCT ID: NCT05988216 Recruiting - Clinical trials for Systemic Lupus Erythematosus (SLE)

Universal CAR-T Cells (BRL-301) in Refractory Systemic Lupus Erythematosus

Start date: August 14, 2023
Phase: N/A
Study type: Interventional

This is an investigator initiated trial to assess the efficacy and safety of BRL-301 in the refractory systemic lupus erythematosus.

NCT ID: NCT05988177 Not yet recruiting - Clinical trials for Hemophagocytic Lymphohistiocytoses

Efficacy and Safety of Carrimycin Tablets in HLH Patients With Carbapenem-resistant Infections

Start date: August 30, 2023
Phase: N/A
Study type: Interventional

This study aimed to investigate the efficacy and safety of Carrimycin tablets in hemophagocytic lymphohistiocytosis patients with Carbapenem-resistant infections.

NCT ID: NCT05988125 Recruiting - Clinical trials for Endovascular Treatment

Prospective Registry Study of Endovascular Treatment for Acute Ischemic Stroke Patients

Start date: January 1, 2017
Phase:
Study type: Observational [Patient Registry]

To investigate the real situation of assessment, diagnosis and treatment of acute ischemic stroke patients with endovascular therapy.

NCT ID: NCT05988073 Recruiting - Clinical trials for Multifocal Motor Neuropathy

A Prospective Longitudinal Study in Adults With Multifocal Motor Neuropathy

Start date: November 29, 2023
Phase:
Study type: Observational

This prospective longitudinal study will follow participants with Multifocal Motor Neuropathy over time and collect data on their clinical outcomes, quality of life, and use of health care resources. Participants will follow their regular visit schedule with their treating physician, except for an optional second visit occurring 7 to 14 days after the start of the study to collect biomarker data. No IMP will be administered.

NCT ID: NCT05987839 Completed - Clinical trials for Total Knee Arthroplasty

Early Radiographic and Clinical Outcomes of Robotic-Arm-Assisted Versus Conventional TKA

TKA
Start date: November 1, 2022
Phase: N/A
Study type: Interventional

Purpose: A robotic system was recently introduced to improve prosthetic alignment during total knee arthroplasty (TKA). The purpose of this multicenter prospective randomized controlled trial (RCT) study was to determine whether robotic-arm-assisted TKA improves the clinical and radiological outcomes in patients compared to conventional TKA. Methods: One hundred and thirty patients who underwent primary TKA were enrolled in this prospective, multicenter RCT conducted in 3 hospitals. Five patients were lost to follow-up at 6 weeks after surgery. Therefore, 125 patients (63 in the intervention group and 62 in the control group) remained in the final analysis. The primary outcome was the rate of patients whose mechanical axis of the femur was less than 3° deviated from the mechanical axis of the tibia evaluated by full-length weight-bearing X-rays of the lower limb at 6 weeks postoperatively. Secondary outcomes will include operation times, 6-week postoperative functional outcomes evaluated by the American Knee Society Score (KSS) and the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), SF-36, adverse events (AEs) and serious adverse events (SAEs). Hypothesis: Robotic-arm-assisted TKA is safe and effective as demonstrated in this trial.